MCID: PLY022
MIFTS: 66

Polycystic Kidney and Hepatic Disease malady

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Reproductive diseases

Aliases & Classifications for Polycystic Kidney and Hepatic Disease

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 23GeneReviews, 24GeneTests, 25Genetics Home Reference, 26GTR, 29ICD10, 30ICD10 via Orphanet, 31ICD9CM, 36MedGen, 38MeSH, 39MESH via Orphanet, 44NCIt, 47NIH Rare Diseases, 49Novoseek, 51OMIM, 53Orphanet, 61SNOMED-CT, 63The Human Phenotype Ontology, 67UMLS, 68UMLS via Orphanet, 69UniProtKB/Swiss-Prot, 70Wikipedia
See all MalaCards sources

Aliases & Descriptions for Polycystic Kidney and Hepatic Disease:

Name: Polycystic Kidney and Hepatic Disease 51 12
Polycystic Kidney Disease 11 70 47 25 13
Arpkd 23 47 24 69 49
Polycystic Kidney Disease, Autosomal Recessive 51 23 24 69
Autosomal Recessive Polycystic Kidney Disease 47 53 67
Polycystic Kidney Diseases 49 38 67
Polycystic Kidney and Hepatic Disease 1 11 69
Polycystic Kidney Disease, Infantile 24 26
Pkd 47 25
Polycystic Kidney Disease 3, Autosomal Dominant 67
Polycystic Kidney Disease, Infantile, Type 1 24
Infantile Polycystic Kidney Disease Type I 69
 
Polycystic Kidney Disease, Infantile Type 47
Polycystic Kidney, Autosomal Recessive 38
Paroxysmal Kinesigenic Choreoathetosis 67
Congenital Biliary Ectasias 11
Polycystic Renal Disease 25
Polycystic Kidneys 47
Pkd, Recessive 24
Pkd, Infantile 24
Arpkd/chf 23
Pkhd1 69
Pkd3 69

Characteristics:

Orphanet epidemiological data:

53
autosomal recessive polycystic kidney disease:
Inheritance: Autosomal recessive; Prevalence: 1-9/100000 (Europe); Age of onset: Childhood

HPO:

63
polycystic kidney and hepatic disease:
Inheritance: autosomal recessive inheritance
Mortality/Aging: neonatal death

GeneReviews:

23
Penetrance: penetrance is 100%; significant intrafamilial variation in disease severity is observed [sweeney & avner 2011, sweeney & avner 2014, sweeney et al 2016]...


Classifications:



External Ids:

OMIM51 263200
Disease Ontology11 DOID:898
ICD1029 Q61.3, Q61.1
ICD9CM31 753.12
NCIt44 C75464
Orphanet53 ORPHA731
MESH via Orphanet39 D017044
UMLS via Orphanet68 C0085548
ICD10 via Orphanet30 Q61.1

Summaries for Polycystic Kidney and Hepatic Disease

About this section
NIH Rare Diseases:47 Autosomal recessive polycystic kidney disease (ARPKD) is a genetic condition that is characterized by the growth of cysts in the kidneys (which lead to kidney failure) and liver and problems in other organs, such as the blood vessels in the brain and heart. The severity varies from person to person. The signs of ARPKD frequently begin before birth, so it is often called “infantile PKD” but some people do not develop symptoms until later in childhood or even adulthood. Children born with ARPKD often, but not always, develop kidney failure before reaching adulthood; babies with the worst cases die hours or days after birth due to respiratory difficulties or respiratory failure. Liver scarring occurs in all patients. The condition is caused by a mutation in the PKHD1 gene and is inherited in an autosomal recessive manner. Some symptoms of the condition may be controlled by medicines, antibiotics, healthy diet, and growth hormones. Last updated: 4/24/2011

MalaCards based summary: Polycystic Kidney and Hepatic Disease, also known as polycystic kidney disease, is related to polycystic kidney disease 2 and polycystic kidney disease, adult type i, and has symptoms including renal insufficiency, polycystic kidney dysplasia and micrognathia. An important gene associated with Polycystic Kidney and Hepatic Disease is PKHD1 (Polycystic Kidney And Hepatic Disease 1 (Autosomal Recessive)), and among its related pathways are Cargo trafficking to the periciliary membrane and TP53 Regulates Metabolic Genes. Affiliated tissues include the kidney, kidney and liver, and related mouse phenotypes are digestive/alimentary and cardiovascular system.

Disease Ontology:11 An autosomal dominant disease characterized by the presence of multiple cysts located in the kidney resulting from ciliopathy that disrupts the function of primary cilium.

Genetics Home Reference:25 Polycystic kidney disease is a disorder that affects the kidneys and other organs. Clusters of fluid-filled sacs, called cysts, develop in the kidneys and interfere with their ability to filter waste products from the blood. The growth of cysts causes the kidneys to become enlarged and can lead to kidney failure. Cysts may also develop in other organs, particularly the liver.

UniProtKB/Swiss-Prot:69 Polycystic kidney disease, autosomal recessive: A severe form of polycystic kidney disease affecting the kidneys and the hepatic biliary tract. The clinical spectrum is widely variable, with most cases presenting during infancy. The fetal phenotypic features classically include enlarged and echogenic kidneys, as well as oligohydramnios secondary to a poor urine output. Up to 50% of the affected neonates die shortly after birth, as a result of severe pulmonary hypoplasia and secondary respiratory insufficiency. In the subset that survives the perinatal period, morbidity and mortality are mainly related to severe systemic hypertension, renal insufficiency, and portal hypertension due to portal-tract fibrosis.

Wikipedia:70 Autosomal recessive polycystic kidney disease (ARPKD) is the recessive form of polycystic kidney... more...

Description from OMIM:51 263200

GeneReviews for NBK1326

Related Diseases for Polycystic Kidney and Hepatic Disease

About this section

Diseases related to Polycystic Kidney and Hepatic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 46)
idRelated DiseaseScoreTop Affiliating Genes
1polycystic kidney disease 212.5
2polycystic kidney disease, adult type i12.4
3polycystic kidney disease 312.3
4polycystic kidney disease, autosomal dominant12.3
5polycystic kidney disease, infantile severe, with tuberous sclerosis12.1
6polycystic kidney disease 1, autosomal dominant12.0
7polycystic kidney disease 2, autosomal dominant12.0
8polycystic liver disease11.4
9orofaciodigital syndrome i11.2
10cystic kidney disease11.2
11orofaciodigital syndrome11.2
12dengue hemorrhagic fever10.6
13chronic interstitial cystitis10.6
14chromosome 16q duplication10.5PKD1, TSC2
15primary autosomal recessive microcephalies and seckel syndrome spectrum disorders10.5PKD1, PKD2
16kohlschutter-tonz syndrome10.4PKD1, TSC2
17craniodiaphyseal dysplasia, autosomal dominant10.3PKD1, PKD2
18xeroderma pigmentosum, variant type10.3PKHD1, PKHD1L1, PLXNC1, TRAM2
19y-linked disease10.2PKD1, PKD2, PKHD1
20gallbladder disease10.1INVS, NPHP3, PKHD1
21hepatitis10.1
22autism 1910.1PKD1, PKD2, PKD2L1
23creatine deficiency syndromes10.1PKD1, PKHD1
24buschke-ollendorff syndrome10.0TSC1, TSC2
25fragile x-associated tremor/ataxia syndrome10.0INVS, NPHP3, PKD1, PKHD1
26mental retardation, anterior maxillary protrusion, and strabismus10.0PKD1, PKD2, PKHD1, PRKCSH, PRKD1
27spinocerebellar ataxia, autosomal recessive 210.0MTOR, TSC1
28liver disease9.9
29renal clear cell carcinoma9.9TSC1, TSC2
30congenital fibrosarcoma9.8MTOR, TSC1, TSC2
31pilomyxoid astrocytoma9.8MTOR, TSC1, TSC2
32cauda equina intradural extramedullary astrocytoma9.8MTOR, TSC1, TSC2
33tenosynovitis of foot and ankle9.8MTOR, TSC1, TSC2
34epithelioid type angiomyolipoma9.8MTOR, TSC1, TSC2
35nephronophthisis 119.8
36caroli disease9.8
37nephronophthisis9.8
38congenital hepatic fibrosis9.8
39medullary sponge kidney9.7
40neonatal infective mastitis9.6MTOR, PKD1, TSC1, TSC2
41focal cortical dysplasia, taylor balloon cell type9.6MTOR, TSC1, TSC2
42dandy-walker syndrome9.6
43urinary tract obstruction9.6
44carbohydrate metabolic disorder9.5EGF, HNF1B, INVS, NPHP3, PKD1, TSC2
45choledochal cyst9.5IFT88, PKD1, PKD2, PKD2L1, PKHD1, PRKD1
46vipoma9.0EPO, IFT88, PKD1, PKD2, PKD2L1, PKHD1

Graphical network of the top 20 diseases related to Polycystic Kidney and Hepatic Disease:



Diseases related to polycystic kidney and hepatic disease

Symptoms for Polycystic Kidney and Hepatic Disease

About this section

Symptoms by clinical synopsis from OMIM:

263200

Clinical features from OMIM:

263200

Human phenotypes related to Polycystic Kidney and Hepatic Disease:

 63 53 (show all 29)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 renal insufficiency63 53 hallmark (90%) Very frequent (99-80%) HP:0000083
2 polycystic kidney dysplasia63 hallmark (90%) HP:0000113
3 micrognathia63 53 hallmark (90%) Very frequent (99-80%) HP:0000347
4 low-set, posteriorly rotated ears63 53 hallmark (90%) Very frequent (99-80%) HP:0000368
5 macrotia63 53 hallmark (90%) Very frequent (99-80%) HP:0000400
6 depressed nasal ridge63 53 hallmark (90%) Very frequent (99-80%) HP:0000457
7 respiratory insufficiency63 53 hallmark (90%) Very frequent (99-80%) HP:0002093
8 congenital hepatic fibrosis63 53 hallmark (90%) Very frequent (99-80%) HP:0002612
9 hypoplasia of the ear cartilage63 53 hallmark (90%) Very frequent (99-80%) HP:0100720
10 biliary tract abnormality63 53 typical (50%) Frequent (79-30%) HP:0001080
11 abnormality of the pancreas63 typical (50%) HP:0001732
12 cystic liver disease63 typical (50%) HP:0006706
13 renal hypoplasia/aplasia63 53 typical (50%) Frequent (79-30%) HP:0008678
14 enlarged kidneys63 HP:0000105
15 renal cyst63 HP:0000107
16 periportal fibrosis63 HP:0001405
17 hepatic cysts63 53 Frequent (79-30%) HP:0001407
18 portal hypertension63 HP:0001409
19 oligohydramnios63 HP:0001562
20 pancreatic cysts63 53 Frequent (79-30%) HP:0001737
21 splenomegaly63 HP:0001744
22 dehydration63 HP:0001944
23 potter facies63 HP:0002009
24 esophageal varix63 HP:0002040
25 pulmonary hypoplasia63 HP:0002089
26 hepatomegaly63 HP:0002240
27 absence of renal corticomedullary differentiation63 HP:0005564
28 tubulointerstitial fibrosis63 HP:0005576
29 multiple renal cysts53 Very frequent (99-80%)

UMLS symptoms related to Polycystic Kidney and Hepatic Disease:


hepatomegaly, dystonia, dystonia, paroxysmal

Drugs & Therapeutics for Polycystic Kidney and Hepatic Disease

About this section

Drugs for Polycystic Kidney and Hepatic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 177)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
CandesartanapprovedPhase 4, Phase 2156139481-59-72541
Synonyms:
139481-59-7
2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid
2-Ethoxy-1-(P-(O-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid
2-Ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid
2-Ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid
2-Ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4ethyl]}-1H-benzimidazole-7-carboxylic acid
2-Ethoxy-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl] methyl]-3H-benzoimidazole-4-carboxylic acid
2-ethoxy-1-({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl)-1H-benzimidazole-7-carboxylic acid
2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid
2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4ethyl}-1H-benzimidazole-7-carboxylic acid
2-ethoxy-3-[[4-[2-(1h-tetrazol-5-yl)phenyl]phenyl]methyl]-3h-benzoimidazole-4-carboxylic acid
2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
2-ethoxy-7-carboxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methylbenzimidazole
AC-203
AC1L1DWT
Amias
Atacand
Atacand, Blopress, Amias, Ratacand,Candesartan
BIDD:GT0350
Blopress
Blopress (TN)
C07468
C081643
C24H20N6O3
CHEBI:216848
 
CHEBI:3347
CHEMBL1016
CID2541
CV 11974
CV-11974
CV11974
Candesartan (USAN/INN)
Candesartan [BAN]
Candesartan [USAN:INN]
Candesartan cilexetil
D00522
DB00796
FT-0083585
HMS2089M22
HSDB 7520
I01-0374
KS-5003
L000156
LS-32740
MolPort-003-845-570
MolPort-005-943-739
NCGC00167474-01
Ratacand
S1578_Selleck
TL8000897
UNII-S8Q36MD2XX
candesartan
2
CilnidipineapprovedPhase 4, Phase 28132203-70-45282138
Synonyms:
(+-)-(E)-Cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl (2E)-3-phenyl-2-propenyl ester
132203-70-4
2-methoxyethyl (2E)-3-phenylprop-2-en-1-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
AC-270
AC1NQZJB
Atelec
Atelec (TN)
BRD-A07875874-001-01-6
Bio-0164
C1493_SIGMA
C27H28N2O7
CHEBI:31399
CHEBI:438069
CHEMBL452076
CID5282138
 
Cilnidipine (JAN/INN)
Cilnidipine [INN]
Cinaldipine
Cinalong
D01173
FRC 8653
FRC-8653
HMS2089J07
I06-0491
LS-131293
MolPort-003-845-950
NCGC00162150-01
NCGC00162150-02
NCGC00162150-03
S1293_Selleck
STK623341
Siscard
cilnidipine
3
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 2, Phase 3, Phase 1362422916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
4
EverolimusapprovedPhase 4, Phase 2, Phase 3, Phase 11896159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
5
Sirolimusapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 1189653123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
6Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 110884
7Adrenergic AgentsPhase 45140
8Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 16972
9Antifungal AgentsPhase 4, Phase 2, Phase 3, Phase 13615
10Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 121402
11Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 112770
12
Candesartan cilexetilPhase 4, Phase 2156145040-37-52540
Synonyms:
(+-)-1-Hydroxyethyl 2-ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylate, cyclohexyl carbonate (ester)
1-(cyclohexylocarbonyloxy)ethyl-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-1H-benzimidazole-7-carboxylate
1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate
145040-37-5
1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester
2-Ethoxy-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester
2-ethoxy-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic acid 1-cyclohe
AC-204
AC1L1DWQ
ATACAND HCT
Almirall brand of candesartan cilexetil
Amias
Astra brand of candesartan cilexetil
AstraZeneca brand of candesartan cilexetil
Atacand
Atacand (TN)
BRD-A65671304-001-02-6
BSPBio_002691
C07709
C077793
C33H34N6O6
CHEBI:216349
CHEMBL1014
CID2540
Candesartan cilexetil
Candesartan cilexetil (JAN/USAN)
Candesartan cilexetil [USAN]
Candesartan hexetil
D00626
FT-0082579
H212/91
 
HMS1922J09
HMS2093E20
I06-0090
KBio2_002187
KBio2_004755
KBio2_007323
KBio3_001911
KBioGR_001607
KBioSS_002187
Kenzen
L006257
LS-32741
MolPort-003-666-552
NCGC00095123-01
NCGC00095123-02
NCGC00095123-03
Parapres
Promed brand of candesartan cilexetil
Racanda
SPBio_000349
SPECTRUM1504261
ST51052687
Spectrum2_000485
Spectrum3_000996
Spectrum4_001124
Spectrum5_001462
Spectrum_001707
TCV 116
TCV-116
TL8000995
Takeda brand of candesartan cilexetil
UNII-R85M2X0D68
candesartan cilexitil
13Angiotensin II Type 1 Receptor BlockersPhase 4, Phase 31078
14
Angiotensin IIPhase 4, Phase 3, Phase 2116268521-88-0, 11128-99-7172198, 65143
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
Ang II
Angiotensin 2
Angiotensin II (human)
 
Angiotensin II (mouse)
Angiotonin
Asp-arg-val-TYR-ile-his-pro-phe
Human angiotensin II
Hypertensin
Ile(5)-angiotensin II
15Adrenergic AntagonistsPhase 41535
16Adrenergic alpha-AntagonistsPhase 4727
17Angiotensin-Converting Enzyme InhibitorsPhase 4, Phase 3, Phase 2711
18Angiotensin Receptor AntagonistsPhase 4, Phase 3, Phase 21173
19Calcium, DietaryPhase 4, Phase 3, Phase 2, Early Phase 15525
20Antihypertensive AgentsPhase 4, Phase 3, Phase 24095
21calcium channel blockersPhase 4, Phase 3, Phase 21940
22AngiotensinogenPhase 4, Phase 3, Phase 21161
23Peripheral Nervous System AgentsPhase 4, Phase 222776
24
CurcuminPhase 4137458-37-7969516
Synonyms:
1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione
1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione
C.I. Natural Yellow 3
CI Natural Yellow 3
Cucurmin
Curcuma
Curcumin
Curcumin I
Diferaloylmethane
Diferuloylmethane
Gelbwurz
Golden seal
Haidr
Halad
Haldar
Halud
Hydrastis
 
Indian saffron
Indian turmeric
Kacha haldi
Kurkumin [czech]
Merita earth
Natural yellow 3
Orange root
Safran D'inde
Souchet
Terra merita
Tumeric yellow
Turmeric
Turmeric (>98% curcurmin)
Turmeric oleoresin (79%-85% curcumin)
Turmeric yellow
Yellow ginger
Yellow puccoon
Yellow root
Yo-kin
Zlut prirodni 3 [Czech]
25Antirheumatic AgentsPhase 410627
26Analgesics, Non-NarcoticPhase 46260
27AnalgesicsPhase 411287
28Anti-Inflammatory AgentsPhase 410355
29Anti-Inflammatory Agents, Non-SteroidalPhase 44295
30
lanreotideapprovedPhase 2, Phase 382108736-35-2
Synonyms:
Lanreotide
 
Lanreotide acetate
Somatuline Depot
31
SomatostatinapprovedPhase 3, Phase 222938916-34-6, 51110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
32
Metoprololapproved, investigationalPhase 320137350-58-6, 51384-51-14171
Synonyms:
(+/-)-Metoprolol
(RS)-Metoprolol
1-(Isopropylamino)-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol
1-(Isopropylamino)-3-(p-(2-methoxyethyl)phenoxy)-2-propanol
1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol
1-[(1-methylethyl)amino]-3-({4-[2-(methyloxy)ethyl]phenyl}oxy)propan-2-ol
1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol
1-[4-(2-methoxyethyl)phenoxy]-3-propan-2-ylamino-propan-2-ol
3-[4-(2-methoxyethyl)phenoxy]-1-(propan-2-ylamino)propan-2-ol
37350-58-6
51384-51-1
54163-88-1
AB00053499
AC-19022
AC1L1HKM
AstraZeneca Brand of Metaoprolol Tartrate
AstraZeneca Brand of Seloken
BRD-A03623303-045-02-0
Beatrolol
Beloc
Beloc Duriles
Beloc-Duriles
BelocDuriles
Betaloc
Betaloc Astra
Betaloc-Astra
BetalocAstra
Betalok
C07202
CCRIS 4198
CGP 2175
CGP-2175
CGP2175
CHEBI:6904
CHEMBL13
CID4171
D008790
D02358
DB00264
DL-metoprolol
Dl-Metoprolol
Dutoprol
EINECS 253-483-7
EINECS 257-166-4
H 93 26
H 93-26
H 9326
 
HMS2090B15
HSDB 6531
I01-7125
I06-0125
Jsp006606
L000669
LOPRESSIDONE
LS-122450
Leiras Brand of Metoprolol Succinate or Metoprolol Tartrate
Lopresor
Lopresoretic
Lopressor
Lopressor HCT
Meijoprolol
Metohexal
Metoprolol
Metoprolol (USAN/INN)
Metoprolol Tartrate
Metoprolol [USAN:INN:BAN]
Metoprolol slow release
Metoprolol succinate
Metoprolol tartrate
Metoprololum
Metoprololum [INN-Latin]
Metroprolol
MolPort-005-938-039
NCGC00021148-02
NCGC00021148-03
NCGC00021148-04
Novartis Brand of Metprolol Tartrate
Preblok
Prelis
Presolol
Selo-Zok
Seloken
Seloken AstraZeneca Brand
Selopral
Seroken
Spesicor
Spesikor
TOPROL-XL
Tartrate, Metoprolol
Toprol
Toprol XL
Toprol-XL
UNII-GEB06NHM23
dl-Metoprolol
metoprolol
33
Lisinoprilapproved, investigationalPhase 311883915-83-75362119
Synonyms:
(2S)-1-[(2S)-6-amino-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]hexanoyl]pyrrolidine-2-carboxylic acid
(S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
(S)-1-(N(2)-(1-carboxy-3-phenylpropyl)-L-lysyl)-L-proline
(S)-1-(N(sup 2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
(S)-1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
1-[Nalpha-[(S)-1-Carboxy-3-phenylpropyl]-L-lysyl]-L-proline
76547-98-3
77726-95-5
83915-83-7 (Parent)
AC1NSFPF
Acerbon
Acercomp
Alapril
BB_NC-1454
BIDD:GT0755
BPBio1_000290
BRD-K67966701-335-03-5
BRN 4276619
BSPBio_000262
C21H31N3O5
CCRIS 3568
CHEBI:43755
CHEMBL1237
CID5362119
Carace
Cipral
Cipril
Coric
D08131
DB00722
DivK1c_001037
Doneka
EINECS 278-488-1
HMS1921B14
HMS2090O14
HMS2092L21
HMS503O15
I06-1895
ICI-209K
IDI1_001037
Inhibril
Inopril
KBio1_001037
KBio2_000977
KBio2_003545
KBio2_006113
KBio3_002002
KBioGR_001599
KBioSS_000977
L0220
LPR
LS-118899
Linopril
Linvas
Lipril
Lisinal
 
Lisinopril
Lisinopril (INN)
Lisinopril (anhydrous)
Lisinopril Dihydrate
Lisinopril anhydrous
Lisinoprilum
Lisinoprilum [Latin]
Lisipril
Lisoril
Lispril
Longes
Loril
Lysinopril
MK 521
MK 522
MK-521
MLS001306436
MLS001306481
MolPort-002-507-428
N(2)-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline
N-(1(S)-Carboxy-3-phenylpropyl)-L-lysyl-L-proline
N2-((S)-1-Carboxy-3-phenylpropyl)-L-lysyl-L-proline
N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline
NCGC00179623-01
NINDS_001037
Noperten
Novatec
Presiten
Prestwick0_000301
Prestwick1_000301
Prestwick2_000301
Prestwick3_000301
Prinil
Prinivil
Prinzide
Renacor
SMR000544473
SPBio_001351
SPBio_002481
SPECTRUM1501217
Sinopril
Sinopryl
Spectrum2_001456
Spectrum3_000941
Spectrum4_001040
Spectrum5_000995
Spectrum_000497
TL8005499
Tensopril
Tensyn
Tersif
Vivatec
Zestoretic
Zestril
Zestril (TN)
[N2-[(S)-1-CARBOXY-3-PHENYLPROPYL]-L-LYSYL-L-PROLINE
[N2-[(S)-1-CARBOXY-3-phenylpropyl]-L-lysyl-L-proline
lisinopril
34
PravastatinapprovedPhase 314981093-37-054687
Synonyms:
(+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid
(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid
3beta-Hydroxycompactin
81093-37-0
81131-70-6 (hydrochloride salt)
AC1L1HJL
AC1Q5T3M
BIDD:GT0773
BRD-K60511616-236-01-4
C01844
C23H36O7
CCRIS 7557
CHEMBL1144
CID54687
Compactin
D08410
DB00175
Elisor
Eptastatin
FT-0082682
KS-5015
LS-94713
Lipostat
Mevalothin
Mevalotin
Mevastatin
Mevinolin
 
Oliprevin
Pravachol
Pravaselect
Pravastatin (INN)
Pravastatin Sodium
Pravastatin Sodium Salt
Pravastatin [INN:BAN]
Pravastatin acid
Pravastatin sodium
Pravastatin tert-Octylamine Salt
Pravastatina
Pravastatina [Spanish]
Pravastatine
Pravastatine [French]
Pravastatinum
Pravastatinum [Latin]
Pravator
Pravator (TN)
RMS-431
SQ-31,000
Selectin
Selektine
Selipran
UNII-KXO2KT9N0G
Vasten
nchembio.301-comp7
nchembio790-comp15
pravastatin
pravastatina
pravastatine
pravastatinum
35
MetforminapprovedPhase 3, Phase 2, Phase 1, Early Phase 11746657-24-914219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMGG
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
36
Octreotideapproved, investigationalPhase 3, Phase 221383150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
 
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
37
HydralazineapprovedPhase 34486-54-43637
Synonyms:
(1Z)-1(2H)-Phthalazinone hydrazone
(2H)-Phthalazinone hydrazone
1(2H)-Phthalazinone hydrazone
1(2H)-Phthalazinone, hydrazone
1-Hydrazinophthalazine
1-Phthalazinylhydrazine
304-20-1 (mono-hydrochloride)
5-25-17-00412 (Beilstein Handbook Reference)
6-Hydralazine
86-54-4
AC1L1GDN
AC1Q4UY1
AKOS000122609
Apresolin
Apresoline
Apressin
Apressin (pharmaceutical)
Apressoline
Aprezolin
BA 5968
BRD-K82103381-003-03-7
BRN 0132615
BSPBio_002130
C 5968
C-5068
C-5968
C07040
C8H8N4
CAS-304-20-1
CCRIS 5385
CHEBI:5775
CHEMBL276832
CID3637
Ciba 5968
D08044
DB01275
DivK1c_000117
EC-000.1838
EINECS 201-680-3
HLZ
Hidral
Hidral (TN)
Hidralazin
Hidralazina
Hidralazina [INN-Spanish]
Hidralazina [Spanish]
Hipoftalin
Hydralazin
Hydralazine (INN)
Hydralazine [INN:BAN]
Hydralazine hydrochloride
 
Hydralazinum
Hydralazinum [INN-Latin]
Hydrallazin
Hydrallazine
Hydrazinophthalazine
Hydrazone 1(2H)-phthalazinone
Hypophthalin
IDI1_000117
Idralazina
Idralazina [DCIT]
Idralazina [Italian]
InChI=1/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12)
KBio1_000117
KBio2_001355
KBio2_003923
KBio2_006491
KBio3_001350
KBioGR_000349
KBioSS_001355
LS-109171
Lopac-H-1753
Lopac0_000593
MolPort-000-876-738
MolPort-001-794-088
NCGC00015501-01
NCGC00015501-02
NCGC00015501-05
NCGC00162199-01
NCIOpen2_001484
NINDS_000117
NSC 126699
NSC126699
Oprea1_207681
Oprea1_416878
Phthalazin-1-ylhydrazine
Praparat 5968
Prestwick0_000169
Prestwick1_000169
Prestwick2_000169
SPBio_000977
SPBio_001958
ST50512087
Spectrum2_000969
Spectrum3_000455
Spectrum4_000005
Spectrum5_000822
Spectrum_000875
UNII-26NAK24LS8
WLN: T66 CNNJ BMZ
ZINC12360535
[2H-Phthalazin-(1Z)-Ylidene]-Hydrazine Hydrochloride
hydralazine
phthalazin-1-ylhydrazine
38
DiltiazemapprovedPhase 37542399-41-739186
Synonyms:
(+)-cis-5-[2-(dimethylamino)Ethyl]-2,3-dihydro-3-hydroxy-2-(P-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester
(+)-cis-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester
(2S,3S)-5-(2-(dimethylamino)Ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate
(2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate
(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate
(2S,3S)-5-[2-(dimethylamino)ethyl]-2-[4-(methyloxy)phenyl]-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate
(2S-cis)-3-(Acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one
(2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one
144604-00-2
33286-22-5
42399-41-7
AC-936
AC1L2181
AC1Q6LHX
Acalix
Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester
Adizem
Aldizem
Altiazem
Anginyl
Angizem
Anoheal
Apo-Diltiaz
BIDD:GT0548
BPBio1_000230
BRD-K24023109-001-02-5
BRD-K24023109-003-03-9
BRN 3573079
BSPBio_000208
BSPBio_001311
Bio1_000371
Bio1_000860
Bio1_001349
Britiazim
Bruzem
C06958
C22H26N2O4S
CHEBI:101278
CHEMBL23
CID39186
Calcicard
Cardil
Cardizem
Cardizem (Hydrochloride)
Cardizem CD
Cardizem SR
Cardizen LA
Cartia XT
Citizem
Cormax
D-cis-Diltiazem
D07845
DB00343
Deltazen
Dilacor
Dilacor-XR
Diladel
Dilcontin
 
Dilpral
Dilren
Dilrene
Dilt-cd
Dilta-Hexal
Diltia
Diltiazem
Diltiazem (INN)
Diltiazem [INN:BAN]
Diltiazemum
Diltiazemum [INN-Latin]
Dilticard
Diltzac
Dilzem
Dilzen
EINECS 255-796-4
Endrydil
FT-0081415
HMS1791B13
HMS1989B13
HMS2089H09
HSDB 6528
Herbesser
Incoril AP
LS-40510
Lopac0_000327
MK-793 (Malate)
Masdil
MolPort-002-509-369
NCGC00024309-02
NCGC00024309-04
NCGC00024309-05
NCGC00024309-06
NCGC00024309-07
NCGC00024309-08
NCGC00024309-09
NCGC00024309-10
Novo-Diltazem
Nu-Diltiaz
Prestwick0_000134
Prestwick1_000134
Prestwick2_000134
Prestwick3_000134
RG 83606 (Hydrochloride)
SPBio_002147
STOCK1N-03672
Surazem (TN)
Syn-Diltiazem
Tiamate
Tiazac
Tiazac Tildiem
Tiazac XC
Tocris-0685
UNII-EE92BBP03H
Viazem
[(2S,3S)-5-(2-dimethylaminoethyl)-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate
d-cis-Diltiazem
diltiazem
nchembio.368-comp1
39
Hydrochlorothiazideapproved, vet_approvedPhase 340558-93-53639
Synonyms:
125727-50-6
3,4-Dihydro-6-chloro-7-sulfamyl-1,2, 4-benzothi
3,4-Dihydrochlorothiazide
58-93-5
6-Chloro-7-sulfamoyl-3, 4-dihy
8049-49-8
AB00052012
AC-11072
AC1L1GDT
AC1Q55FM
AF-614/30832002
AKOS000121373
ARONIS24316
Acesistem
Acuilix
Acuretic
Aldactazide
Aldactazide 25/25
Aldazida
Aldectazide 50/50
Aldoril
Ambap58-93-5
Apo-Hydro
Apresazide
Aquarills
Aquarius
Aquazide H
Aquazide-H
BAS 00371709
BIDD:GT0153
BPBio1_000019
BRD-K13078532-001-05-2
BRN 0625101
BSPBio_000017
BSPBio_002132
Bio-0714
Bremil
Briazide
C7H8ClN3O4S2
CAS-58-93-5
CCRIS 2082
CHEMBL435
CID3639
CPD000035778
Caplaril
Capozide
Carozide
Catiazida
Chlorizide
Chlorosulthiadil
Chlorothiazide
Chlorsulfonamidodihydrobenzothiadiazine dioxide
Chlorzide
Chlothia
Cidrex
Clorana
Component of Butizide Prestabs
Concor Plus
Condiuren
D00340
D006852
DB00999
Diaqua
Dichlorosal
Dichlorotride
Dichlothiazide
Dichlotiazid
Dichlotride
Diclotride
Dicyclotride
Didral
Dihydran
Dihydrochlorothiazid
Dihydrochlorothiazide
Dihydrochlorothiazidum
Dihydrochlorurit
Dihydrochlorurite
Dihydroxychlorothiazidum
Direma
Disalunil
Disothiazid
Diu 25 Vigt
Diu-Melusin
Diu-melusin
Diuril
Diurogen
DivK1c_000289
Dixidrasi
Drenol
Dyazide
EINECS 200-403-3
EU-0100614
Esidrex
Esidrix
Esidrix (TN)
Esimil
Esoidrina
FT-0082750
Fluvin
H 4759
H1274
H2910_SIAL
H4759_SIAL
HCT
HCT-Isis
HCTZ
HCZ
HMS1568A19
HMS1920D19
HMS2091L05
HMS500O11
HMS553N04
HSDB 3096
Hidril
Hidro-Niagrin
Hidrochlortiazid
Hidroclorotiazida
Hidroclorotiazida [INN-Spanish]
Hidroronol
Hidrosaluretil
Hidrotiazida
Hyclosid
Hydrex-semi
Hydril
Hydro Par
Hydro-Aquil
Hydro-D
Hydro-Diuril
Hydro-Saluric
Hydro-T
Hydro-chlor
HydroDIURIL
Hydrochlorat
Hydrochloro Thiazide
Hydrochlorot
Hydrochlorothiazid
Hydrochlorothiazide
Hydrochlorothiazide (JP15/USP/INN)
Hydrochlorothiazide Intensol
Hydrochlorothiazide [INN:BAN:JAN]
 
Hydrochlorothiazidum
Hydrochlorothiazidum [INN-Latin]
Hydrochlorthiazide
Hydrochlorthiazidum
Hydrocot
Hydrodiuretic
Hydrodiuril
Hydropres
Hydrosaluric
Hydrothide
Hydrozide
Hydrozide Injection, Veterinary
Hypothiazid
Hypothiazide
Hytrid
Hyzaar
I09-0531
IDI1_000289
Idroclorotiazide
Idroclorotiazide [DCIT]
Idrotiazide
Inderide
Inderide 80/25
Indroclor
Ivaugan
Jen-Diril
KBio1_000289
KBio2_001357
KBio2_003925
KBio2_006493
KBio3_001352
KBioGR_000351
KBioSS_001357
LS-243
Lopac-H-4759
Lopac0_000614
Lopressor HCT
Lotensin HCT
Lotensin Hct
MLS000069619
Manuril
Maschitt
Maxzide
Maybridge Compound 10
Maybridge1_004336
Mazide 25 mg
Medozide
Megadiuril
Microzide
Microzide (TN)
Mictrin
Mikorten
Modurcen
Moduretic
MolPort-000-144-465
NCGC00015508-01
NCGC00015508-02
NCGC00015508-03
NCGC00015508-07
NCGC00015508-12
NCGC00021906-03
NCGC00021906-04
NCGC00021906-05
NCGC00021906-06
NCGC00021906-07
NCGC00021906-08
NCI-C55925
NCI60_004317
NINDS_000289
NSC 53477
NSC53477
Natrinax
Nefrix
Nefrol
Neo-Codema
Neo-Flumen
Neo-Minzil
Neo-codema
Neoflumen
Newtolide
Novodiurex
Oprea1_357174
Oretic
Pantemon
Panurin
Prestwick0_000009
Prestwick1_000009
Prestwick2_000009
Prestwick3_000009
Prestwick_263
Prinzide
Raunova Plus
Ro-Hydrazide
Ro-hydrazide
Roxane
S1708_Selleck
SAM002554901
SMR000035778
SPBio_001259
SPBio_001938
SPECTRUM1500335
STK315354
Saldiuril
Sectrazide
Selozide
Ser-Ap-Es
Servithiazid
Spectrum2_001040
Spectrum3_000456
Spectrum4_000006
Spectrum5_000824
Spectrum_000877
Spironazide
Su 5879
Tandiur
Thiaretic
Thiuretic
Thlaretic
Timolide
UNII-0J48LPH2TH
Unazid
Unipres
Urodiazin
Urozide
Vaseretic
Vetidrex
WLN: T66 BSWM EM DHJ HG ISZW
ZINC00896569
Ziac
Zide
adiazine-1,1-dioxide
component of Aldactazide
component of Aldoril
component of Caplaril
component of Cyclex
component of Dyazide
component of Esimil
diclot ride
dro-2H-1,2,4-benzothiadiazine 1,1-dioxide
hydrochlorothiazide
panurin dichloride
40
ClonidineapprovedPhase 32264205-90-72803
Synonyms:
1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro- (9CI)
2,6-Dichloro-N-2-imidazolidinylidenebenzenamine
2,6-dichloro-N-(2-imidazolidinylidene)aniline
2,6-dichloro-N-2-imidazolidinylidenebenzenamide
2,6-dichloro-N-imidazolidin-2-ylideneaniline
2-((2,6-Dichlorophenyl)imino)imidazolidine
2-(2,6-Dichloroanilino)-1,3-diazacyclopentene-(2)
2-(2,6-Dichloroanilino)-2-imidazoline
2-(2,6-Dichlorophenylamino)-2-imidazoline
2-(2,6-Dichlorophenylimino)imidazolidine
2-Imidazoline, 2-(2,6-dichloroanilino)- (7CI,8CI)
2-[(2,6-Dichlorophenyl)imino]imidazoline
2-[(2,6-dichlorophenyl)imino]-2-imidazoline
4205-90-7
4205-91-8 (mono-hydrochloride)
57066-25-8
734571A
AB00514634
AC1L1EI5
AC1Q3K6V
AKOS001595470
Adesipress
BIDD:GT0547
BPBio1_000040
BRD-K98530306-001-02-1
BRD-K98530306-003-05-0
BSPBio_000036
BSPBio_001588
BSPBio_002055
Bio1_000470
Bio1_000959
Bio1_001448
Bio2_000308
Bio2_000788
C9H9Cl2N3
CAS-4205-91-8
CATAPRES-TTS-1
CATAPRES-TTS-2
CATAPRES-TTS-3
CCRIS 7787
CHEBI:3757
CHEBI:46632
CHEMBL134
CID2803
Catapres
Catapres- TTS
Catapres-TTS
Catapresan
Catapressan
Catarpres
Catarpres-TTS
Catarpres-TTS (TN)
Catarpresan
Chlofazoline
Chlornidinum
Clofenil
Clonidin
Clonidina
Clonidina [INN-Spanish]
Clonidine (JAN/USAN/INN)
Clonidine HCl
Clonidine [USAN:BAN:INN]
Clonidinhydrochlorid
Clonidinum
Clonidinum [INN-Latin]
Clonistada
Clopheline
D00281
DB00575
DB07566
DivK1c_000774
 
Dixarit
Duraclon
Duraclont
EINECS 224-119-4
Gemiton
HMS1361P10
HMS1791P10
HMS1989P10
HMS2089G11
HSDB 3040
Hemiton
IDI1_000774
IDI1_034058
Ipotensium
Isoglaucon
KBio1_000774
KBio2_000308
KBio2_001821
KBio2_002876
KBio2_004389
KBio2_005444
KBio2_006957
KBio3_000615
KBio3_000616
KBio3_001275
KBioGR_000308
KBioGR_001572
KBioSS_000308
KBioSS_001821
Klofelin
Klofenil
L000193
LS-79606
Lopac-C-7897
Lopac0_000268
M 5041T
M-5041T
MolPort-001-779-668
MolPort-005-932-374
N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine
NCGC00015268-01
NCGC00015268-02
NCGC00015268-08
NCGC00024734-01
NCGC00024734-02
NCGC00024734-03
NCGC00024734-04
NCGC00024734-05
NCGC00179680-01
NINDS_000774
Prestwick0_000248
Prestwick1_000248
Prestwick2_000248
Prestwick3_000248
SKF 34427
SPBio_001233
SPBio_002255
ST 155BS
ST-155-BS
ST-155BS
Spectrum2_001187
Spectrum3_000358
Spectrum4_000956
Spectrum5_000759
Spectrum_001341
T171
Tenso-Timelets
Tocris-0690
UNII-MN3L5RMN02
ZINC00896484
clonidine
nchembio.79-comp11
nchembio705-10
41
Telmisartanapproved, investigationalPhase 3264144701-48-465999
Synonyms:
144701-48-4
2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid
4'-((1,4'-Dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid
4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid
4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid
4'-((4-mehtyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimmidazolyl)methyl)-2-biphenylcarboxylic acid
4'-[(1,4'-Dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid
4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid
4'-[(1,7'-Dimethyl-2'-propyl-1H,3'h-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid
4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl][1,1'-biphenyl]-2-carboxylic acid
4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid
AC-2013
AC1L24EB
AC1Q5U7O
Abbott brand of telmisartan
BAY-68-9291
BAY68-9291
BIBR 277
BIBR 277SE
BIBR-277
BIBR-277-SE
BIBR-277SE
BIDD:GT0365
BRD-K73999723-001-02-2
BSPBio_002738
Bay 68-9291
Bio-0103
Boehringer Ingelheim brand of telmisartan
C07710
C084178
C33H30N4O2
CHEBI:9434
CHEMBL1017
CID65999
CPD000466326
D00627
DB00966
Glaxo Wellcome brand of telmisartan
GlaxoSmithKline brand of telmisartan
 
HMS1922P07
HMS2051P16
HMS2090P17
HMS2093M22
HSDB 7590
I06-0281
KBio3_001958
KBioGR_001842
Kinzal
Kinzalmono
L001035
LS-44263
MLS000759432
MLS001076687
Micardis
Micardis (TN)
Micardis HCT
Micardis, Targit, Temax, BIBR277, Telmisartan
MolPort-003-666-621
NCGC00095150-01
NCGC00095150-02
NCGC00095150-03
Pritor
S1738_Selleck
SAM001246602
SMR000466326
SPBio_002131
SPECTRUM1505261
STK624049
Spectrum2_001976
Spectrum3_001089
Spectrum4_001261
Spectrum5_001053
TL8000991
Telmisartan
Telmisartan (JAN/USAN/INN)
Telmisartan [USAN:INN]
UNII-U5SYW473RQ
YM-086
telmisartan
42
TolvaptanapprovedPhase 3, Phase 289150683-30-0216237
Synonyms:
( -)-4'-((7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl)-o-tolu-m-toluidide
150683-30-0
7-Chloro-5-hydroxy-1-(2-methyl-4-(2-methylbenzoylamino)benzoyl)2,3,4,5-tetrahydro-1H-1-benzazepine
AC1L50C9
C116664
CHEBI:327437
CHEMBL344159
CID216237
 
L001628
N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide
OPC 41061
OPC-41061
PDSP1_001738
PDSP2_001721
Samsca
Tolvaptan
UNII-21G72T1950
benzazepine derivative, 32
43
MinoxidilapprovedPhase 33438304-91-54201
Synonyms:
16317-69-4
2,3-Dihydro-3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine
2,4-Diamino-6-piperidinilpirimidina-3-ossido
2,4-Diamino-6-piperidinilpirimidina-3-ossido [Italian]
2,4-Diamino-6-piperidino-pyrimidine-3-oxide
2,4-Diamino-6-piperidinopyrimidine 3-N-oxide
2,4-Diamino-6-piperidinopyrimidine 3-oxide
2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide
2,6-Diamino-4-piperidinopyrimidin-1-oxid
3-hydroxy-2-imino-6-(1-piperidyl)pyrimidin-4-amine
3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine
38304-91-5
5-25-12-00317 (Beilstein Handbook Reference)
6-(1-Piperidinyl)-2,4-pyrimidinediamine 3-oxide
6-(piperidin-1-yl)pyrimidine-2,4-diamine 3-oxide
6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine
6-Piperidin-1-ylpyrimidine-2,4-diamine 3-oxide
6-Piperidino-2,4-diaminopyrimidine 3-oxide
6-[1-Piperidinyl]pyrimidine-2,4-diamine 3 oxide
AB00513797
AC-5271
AC1L1HN1
Alopexil
Alostil
Ambap38304-91-5
Apo-Gain
Apo-gain
BCBcMAP01_000193
BPBio1_000065
BRD-K06902185-001-05-2
BRD-K14888893-001-02-3
BRN 0886240
BSPBio_000059
BSPBio_001385
BSPBio_002037
Bio1_000084
Bio1_000573
Bio1_001062
Bio2_000105
Bio2_000585
C9H15N5.H2O
CAS-38304-91-5
CBiol_001798
CHEBI:49774
CHEBI:6942
CHEMBL609587
CHEMBL802
CID4201
CPD-7668
CPD000058963
D00418
D008914
DB00350
DB08225
DivK1c_000160
EINECS 253-874-2
EU-0100786
Gen-Minoxidil
HMS1361F07
HMS1568C21
HMS1791F07
HMS1920P03
HMS1989F07
HMS2089L08
HMS2091F20
HMS500H22
HSDB 6538
IDI1_000160
IDI1_033855
Jsp006715
KBio1_000160
KBio2_000105
KBio2_001449
KBio2_002673
KBio2_004017
KBio2_005241
KBio2_006585
KBio3_000209
KBio3_000210
KBio3_001537
KBioGR_000105
KBioGR_000585
KBioSS_000105
KBioSS_001449
LS-135040
Loniten
Loniten (TN)
Lonolox
Lopac-M-4145
 
Lopac0_000786
M 4145
M1389
MINOXIDIL (FOR MEN)
MINOXIDIL (FOR WOMEN)
MINOXIDIL EXTRA STRENGTH (FOR MEN)
MINOXIDIL EXTRA STRENGTH FOR MEN
MLS000028566
MLS000859953
MLS001077294
Men s Rogaine Foam
Men's Rogaine
Mens Rogaine Foam
Minodyl
Minossidile
Minossidile [Italian]
Minoxidil
Minoxidil (USP/INN)
Minoxidil Pfizer Brand
Minoxidil [USAN:BAN:INN]
Minoxidilum
Minoxidilum [INN-Latin]
Minoxigaine
Minoximen
MolPort-003-666-236
MolPort-005-932-694
NCGC00015673-01
NCGC00015673-02
NCGC00015673-04
NCGC00015673-11
NCGC00018278-01
NCGC00024666-01
NCGC00024666-02
NCGC00024666-03
NCGC00024666-04
NCGC00024666-05
NCGC00024666-06
NCGC00024666-07
NCGC00024666-08
NCGC00179672-01
NINDS_000160
Neoxidil
Normoxidil
Pfizer Brand of Minoxidil
Pierminox
Prestwick0_000020
Prestwick1_000020
Prestwick2_000020
Prestwick3_000020
Prestwick_521
Prexidil
Pyrimidine, 2,4-diamino-6-piperidino-, 3-oxide
ROGAINE (FOR MEN)
ROGAINE (FOR WOMEN)
ROGAINE EXTRA STRENGTH (FOR MEN)
Regaine
RiUP
Riup (TN)
Rogaine
Rogaine (TN)
Rogaine Extra Strength for Men
Rogaine for Men
Rogaine for Women
Rogaine, Regaine, Avacor and Mintop, Minoxidil
S1383_Selleck
SAM002589949
SBB056986
SGCUT00112
SMP1_000192
SMR000058963
SMR000326812
SPBio_001006
SPBio_001980
SPECTRUM1500415
Spectrum2_001053
Spectrum3_000509
Spectrum4_000063
Spectrum5_001299
Spectrum_000969
TM-160
Theroxidil
Tocris-0583
Tricoxidil
Trocoxidil
U 10858
U-10,858
U-10858
ZINC00001735
minoxidil
nchembio.79-comp10
to_000070
44
BenzocaineapprovedPhase 2, Phase 318921994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Caswell No. 430A
Chloraseptic
D001566
D00552
DB01086
Dermoplast
Diet Ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
 
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Formate, Benzocaine
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
MLS001331704
MLS002153970
Methanesulfonate, Benzocaine
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Norcain
Norcaine
Norcainum
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orthesin
Otocain
Outgro
Parathesin
Parathesin (TN)
Parathesine
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
45tannic acidapproved, NutraceuticalPhase 2, Phase 31892
46
protease inhibitorsPhase 3, Phase 25320
Synonyms:
 
protease inhibitors
47HIV Protease InhibitorsPhase 3, Phase 25319
48Contraceptive AgentsPhase 31901
49Liver ExtractsPhase 2, Phase 33868
50AngiopeptinPhase 2, Phase 382

Interventional clinical trials:

(show top 50)    (show all 121)
idNameStatusNCT IDPhase
1CCB Safety Study in Treatment of Hypertension of ADPKDUnknown statusNCT00541853Phase 4
2Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT00414440Phase 4
3Weight Loss Improves Renal HemodynamicsCompletedNCT01356394Phase 4
4Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKDRecruitingNCT02494141Phase 4
5Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)Unknown statusNCT02115659Phase 3
6Sirolimus for Massive Polycystic LiverUnknown statusNCT01680250Phase 2, Phase 3
7Open-Label Extension of LOCKCYST TrialUnknown statusNCT00771888Phase 2, Phase 3
8Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00456365Phase 3
9Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00346918Phase 3
10Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up StudyCompletedNCT00309283Phase 3
11A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]CompletedNCT01022424Phase 3
12A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]CompletedNCT01280721Phase 3
13HALT Progression of Polycystic Kidney Disease (HALT PKD) Study BCompletedNCT01885559Phase 3
14HALT Progression of Polycystic Kidney Disease (HALT PKD) Study ACompletedNCT00283686Phase 3
15Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT02225860Phase 2, Phase 3
16Effects of Somatostatin on Liver in ADPKDCompletedNCT02119052Phase 2, Phase 3
17Open-Label Tolvaptan Study in Subjects With ADPKDCompletedNCT01214421Phase 3
18Tolvaptan Phase 3 Efficacy and Safety Study in ADPKDCompletedNCT00428948Phase 3
19Effects of Somatostatin on ADPKD HeartCompletedNCT02119013Phase 2, Phase 3
20Octreotide in Severe Polycystic Liver DiseaseCompletedNCT00426153Phase 2, Phase 3
21Lanreotide as Treatment of Polycystic LiversCompletedNCT00565097Phase 2, Phase 3
22Efficacy and Safety of Tolvaptan in Cirrhotic Patients With HyponatremiaCompletedNCT01850940Phase 3
23Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver DiseaseCompletedNCT01315795Phase 2, Phase 3
24Lanreotide In Polycystic Kidney Disease StudyRecruitingNCT02127437Phase 3
25The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted RecipientsRecruitingNCT02134899Phase 3
26Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)RecruitingNCT02964273Phase 3
27Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney DiseaseRecruitingNCT02055079Phase 3
28Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)RecruitingNCT01733459Phase 3
29PCOS Treatment Using DLBS3233, Metformin, and Combination of BothRecruitingNCT01999686Phase 3
30Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney DiseaseActive, not recruitingNCT02160145Phase 3
31Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal InsufficiencyActive, not recruitingNCT01377246Phase 3
32Study of Lanreotide to Treat Polycystic Kidney DiseaseActive, not recruitingNCT01616927Phase 3
33Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney DiseaseEnrolling by invitationNCT02251275Phase 3
34Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal InsufficiencyTerminatedNCT01223755Phase 2, Phase 3
35Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to TherapyTerminatedNCT00920309Phase 2, Phase 3
36Everolimus on CKD Progression in ADPKD PatientsTerminatedNCT01009957Phase 2, Phase 3
37Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)Unknown statusNCT00890279Phase 2
38Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression ControlUnknown statusNCT01932450Phase 2
39Bosutinib For Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT01233869Phase 2
40Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney DiseaseCompletedNCT02140814Phase 2
41Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00286156Phase 1, Phase 2
428-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT01451827Phase 2
43A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]CompletedNCT00841568Phase 2
44Short-Term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT01336972Phase 2
45Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKDCompletedNCT01210560Phase 2
46Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and SafetyCompletedNCT00491517Phase 2
47Tolvaptan Open-Label Pilot Efficacy, Tolerability and Safety Study in ADPKDCompletedNCT00413777Phase 2
48Ursodeoxycholic Acid as Treatment for Polycystic Liver DiseaseCompletedNCT02021110Phase 2
49Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney DiseaseRecruitingNCT02656017Phase 2
50Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney DiseaseRecruitingNCT02697617Phase 2

Search NIH Clinical Center for Polycystic Kidney and Hepatic Disease


Cochrane evidence based reviews: polycystic kidney, autosomal recessive

Genetic Tests for Polycystic Kidney and Hepatic Disease

About this section

Genetic tests related to Polycystic Kidney and Hepatic Disease:

id Genetic test Affiliating Genes
1 Polycystic Kidney Disease, Infantile Type26
2 Polycystic Kidney Disease, Autosomal Recessive24 PKHD1

Anatomical Context for Polycystic Kidney and Hepatic Disease

About this section

MalaCards organs/tissues related to Polycystic Kidney and Hepatic Disease:

35
Kidney, Liver, Ovary, Heart, Brain, Endothelial, Bone marrow

FMA organs/tissues related to Polycystic Kidney and Hepatic Disease:

17
The kidney

Animal Models for Polycystic Kidney and Hepatic Disease or affiliated genes

About this section

MGI Mouse Phenotypes related to Polycystic Kidney and Hepatic Disease:

40 (show all 14)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053819.5CFTR, EGF, IFT88, INVS, PKD1, PKD2
2MP:00053858.4EPO, IFT88, INVS, NPHP3, PKD1, PKD2
3MP:00053878.3CFTR, EGF, EPO, HNF1B, INVS, MTOR
4MP:00053808.3EPO, HNF1B, IFT88, INVS, MTOR, NPHP3
5MP:00053798.3CFTR, EGF, HNF1B, IFT88, INVS, MTOR
6MP:00053978.3AVPR2, CFTR, EPO, INVS, MTOR, NPHP3
7MP:00053708.1CFTR, EPO, HNF1B, IFT88, INVS, PKD1
8MP:00028738.0CFTR, EGF, EPO, MTOR, PKD1, PKD2
9MP:00053677.9AVPR2, HNF1B, IFT88, INVS, MTOR, NPHP3
10MP:00053887.6CFTR, EPO, IFT88, INVS, MTOR, PKD1
11MP:00053847.3EPO, IFT88, INVS, MTOR, NPHP3, PKD1
12MP:00053787.1AVPR2, CFTR, EGF, HNF1B, IFT88, INVS
13MP:00053766.8AVPR2, CFTR, EPO, HNF1B, IFT88, INVS
14MP:00107686.2AVPR2, CFTR, EPO, HNF1B, IFT88, INVS

Publications for Polycystic Kidney and Hepatic Disease

About this section

Articles related to Polycystic Kidney and Hepatic Disease:

idTitleAuthorsYear
1
Renal cystic disease and liver abnormalities: polycystic kidney and hepatic disease and the association with caroli disease. (25907884)
2015
2
Congenital Hepatic Fibrosis in the Franches-Montagnes Horse Is Associated with the Polycystic Kidney and Hepatic Disease 1 (PKHD1) Gene. (25295861)
2014
3
Polycystic kidney and hepatic disease with mental retardation is nephronophthisis 11 caused by MKS3/TMEM67 mutations. (20607301)
2010
4
PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like-plexin- transcription-factor domains and parallel beta-helix 1 repeats. (11898128)
2002
5
Genomic organization of the KIAA0057 gene that encodes a TRAM-like protein and its exclusion as a polycystic kidney and hepatic disease 1 (PKHD1) candidate gene. (10594243)
1999

Variations for Polycystic Kidney and Hepatic Disease

About this section

UniProtKB/Swiss-Prot genetic disease variations for Polycystic Kidney and Hepatic Disease:

69 (show all 100)
id Symbol AA change Variation ID SNP ID
1PKHD1p.Thr36MetVAR_014039rs28939383
2PKHD1p.Ile222ValVAR_014040rs369925690
3PKHD1p.Phe253LeuVAR_014041rs775254013
4PKHD1p.Arg760HisVAR_014044rs745770404
5PKHD1p.Gly1122SerVAR_014046
6PKHD1p.Cys1249TrpVAR_014048rs748540413
7PKHD1p.Leu1407ArgVAR_014050
8PKHD1p.Ser1664PheVAR_014052rs28937907
9PKHD1p.Val1741MetVAR_014053rs28939099
10PKHD1p.Gln1917ArgVAR_014054
11PKHD1p.Glu1995GlyVAR_014055
12PKHD1p.Ile2331LysVAR_014056rs200179145
13PKHD1p.Ile2957ThrVAR_014058rs760222236
14PKHD1p.Ser3018PheVAR_014059rs137852945
15PKHD1p.Ile3553ThrVAR_014061rs137852948
16PKHD1p.Ala17ValVAR_018520rs755654557
17PKHD1p.Gly223SerVAR_018522rs749454235
18PKHD1p.Ile307ThrVAR_018523
19PKHD1p.Gly326ValVAR_018524rs778329699
20PKHD1p.Ile473SerVAR_018527
21PKHD1p.Tyr486HisVAR_018528
22PKHD1p.Arg496ProVAR_018530
23PKHD1p.Trp656CysVAR_018532
24PKHD1p.Asp703AsnVAR_018533
25PKHD1p.Pro739LeuVAR_018535rs758352210
26PKHD1p.Ile757LeuVAR_018536rs777183511
27PKHD1p.Pro805LeuVAR_018537rs199531851
28PKHD1p.Asn830SerVAR_018538rs62406032
29PKHD1p.Thr899ProVAR_018539
30PKHD1p.Met997LysVAR_018540
31PKHD1p.Ala1030GluVAR_018541
32PKHD1p.Gly1123SerVAR_018542rs142107837
33PKHD1p.Pro1389ThrVAR_018546
34PKHD1p.Cys1472TyrVAR_018547
35PKHD1p.Pro1486LeuVAR_018548
36PKHD1p.Ser1584IleVAR_018549
37PKHD1p.Thr1781IleVAR_018551
38PKHD1p.Val1789LeuVAR_018552
39PKHD1p.Ser1833LeuVAR_018553rs201105958
40PKHD1p.Tyr1838CysVAR_018554rs777999875
41PKHD1p.Ser1867AsnVAR_018555
42PKHD1p.Asp1942GlyVAR_018557
43PKHD1p.Gly1971AspVAR_018558rs180675584
44PKHD1p.Ile1998ThrVAR_018559
45PKHD1p.Val2032LeuVAR_018560
46PKHD1p.Leu2134ProVAR_018561
47PKHD1p.Ile2303PheVAR_018562rs751084512
48PKHD1p.Cys2422GlyVAR_018563rs201881567
49PKHD1p.Thr2641AlaVAR_018565rs7766366
50PKHD1p.Cys2688PheVAR_018566
51PKHD1p.Asp2761TyrVAR_018567
52PKHD1p.Leu2772ProVAR_018568
53PKHD1p.Ser2861GlyVAR_018569rs150925674
54PKHD1p.Tyr2863CysVAR_018570
55PKHD1p.Thr2869LysVAR_018571rs142522748
56PKHD1p.Asp2962GlyVAR_018572
57PKHD1p.Ser2983LeuVAR_018573rs141169758
58PKHD1p.Val3036GlyVAR_018574
59PKHD1p.Ile3081ValVAR_018576rs142146981
60PKHD1p.His3124TyrVAR_018579
61PKHD1p.Ile3167LeuVAR_018581
62PKHD1p.Asn3175AspVAR_018582
63PKHD1p.Asn3175SerVAR_018583
64PKHD1p.Ile3177ThrVAR_018584rs200511261
65PKHD1p.Asp3293ValVAR_018586
66PKHD1p.Cys3346ArgVAR_018587rs149798764
67PKHD1p.Ile3468ValVAR_018589rs748863662
68PKHD1p.Val3471GlyVAR_018590rs137852950
69PKHD1p.Arg3482CysVAR_018591rs148617572
70PKHD1p.Glu3502ValVAR_018592
71PKHD1p.Glu3529GlnVAR_018594rs145184792
72PKHD1p.Cys3622TyrVAR_018596
73PKHD1p.Pro3783SerVAR_018597
74PKHD1p.Phe372LeuVAR_027439
75PKHD1p.Arg92TrpVAR_066416rs370277502
76PKHD1p.Ile246ThrVAR_066417
77PKHD1p.Tyr255CysVAR_066418
78PKHD1p.Ala293ValVAR_066420rs398124499
79PKHD1p.Gly466GluVAR_066421
80PKHD1p.Gly470ValVAR_066422rs776845008
81PKHD1p.Ile539ThrVAR_066423rs749730748
82PKHD1p.His686ProVAR_066424
83PKHD1p.Pro724ArgVAR_066426
84PKHD1p.Val1817GlyVAR_066428
85PKHD1p.Val1875GlyVAR_066429rs202016058
86PKHD1p.Trp1928LeuVAR_066430
87PKHD1p.Ala2009ThrVAR_066431rs761786260
88PKHD1p.Leu2106ArgVAR_066432
89PKHD1p.Gly2210GluVAR_066433
90PKHD1p.Ser2219LeuVAR_066434
91PKHD1p.Gly2224ArgVAR_066435rs759687904
92PKHD1p.Cys2422ArgVAR_066436rs201881567
93PKHD1p.Glu2431ValVAR_066437
94PKHD1p.Arg2573CysVAR_066438rs752994816
95PKHD1p.Val2798GlyVAR_066440
96PKHD1p.Cys2803ArgVAR_066441rs398124495
97PKHD1p.Met2804LysVAR_066442rs794727759
98PKHD1p.His3049ArgVAR_066443rs367678592
99PKHD1p.Ala3207ThrVAR_066444
100PKHD1p.Arg3957CysVAR_066446rs146680689

Clinvar genetic disease variations for Polycystic Kidney and Hepatic Disease:

5 (show all 140)
id Gene Variation Type Significance SNP ID Assembly Location
1PKHD1NM_138694.3(PKHD1): c.9719G> T (p.Arg3240Leu)SNVLikely pathogenicrs146649803GRCh38Chr 6, 51747897: 51747897
2PKHD1NM_138694.3(PKHD1): c.6499C> T (p.Gln2167Ter)SNVPathogenicrs368263958GRCh38Chr 6, 51909466: 51909466
3PKHD1NM_138694.3(PKHD1): c.5895dupA (p.Leu1966Thrfs)duplicationPathogenicrs746838237GRCh37Chr 6, 51824681: 51824681
4PKHD1NM_138694.3(PKHD1): c.4733delA (p.Tyr1578Phefs)deletionPathogenicrs727504087GRCh37Chr 6, 51889875: 51889875
5PKHD1NM_138694.3(PKHD1): c.2725C> T (p.Arg909Ter)SNVPathogenicrs727504089GRCh38Chr 6, 52043721: 52043721
6PKHD1NM_138694.3(PKHD1): c.370C> T (p.Arg124Ter)SNVPathogenicrs727504096GRCh38Chr 6, 52079920: 52079920
7PKHD1NM_138694.3(PKHD1): c.8303-1G> ASNVPathogenicrs786204241GRCh38Chr 6, 51791374: 51791374
8PKHD1NM_138694.3(PKHD1): c.4870C> T (p.Arg1624Trp)SNVLikely pathogenic, Pathogenicrs200391019GRCh38Chr 6, 52024940: 52024940
9PKHD1NM_138694.3(PKHD1): c.3766delC (p.Gln1256Argfs)deletionLikely pathogenicrs746972457GRCh38Chr 6, 52026044: 52026044
10PKHD1NM_138694.3(PKHD1): c.11524C> T (p.Arg3842Ter)SNVLikely pathogenicrs746471701GRCh37Chr 6, 51497504: 51497504
11PKHD1NM_138694.3(PKHD1): c.6992T> A (p.Ile2331Lys)SNVLikely pathogenic, Pathogenicrs200179145GRCh37Chr 6, 51768399: 51768399
12PKHD1NM_138694.3(PKHD1): c.2279G> A (p.Arg760His)SNVLikely pathogenicrs745770404GRCh37Chr 6, 51914955: 51914955
13PKHD1NM_138694.3(PKHD1): c.10444C> T (p.Arg3482Cys)SNVLikely pathogenic, Pathogenicrs148617572GRCh37Chr 6, 51524480: 51524480
14PKHD1NM_138694.3(PKHD1): c.3367G> A (p.Gly1123Ser)SNVLikely pathogenicrs142107837GRCh37Chr 6, 51893147: 51893147
15PKHD1NM_138694.3(PKHD1): c.711_714delAATG (p.Met238Serfs)deletionLikely pathogenic, Pathogenicrs786204588GRCh37Chr 6, 51934319: 51934322
16PKHD1NM_138694.3(PKHD1): c.1480C> T (p.Arg494Ter)SNVLikely pathogenic, Pathogenicrs754392766GRCh37Chr 6, 51923153: 51923153
17PKHD1NM_138694.3(PKHD1): c.10452dupT (p.Leu3485Serfs)duplicationLikely pathogenicrs771623148GRCh37Chr 6, 51524472: 51524472
18PKHD1NM_138694.3(PKHD1): c.9319C> T (p.Arg3107Ter)SNVLikely pathogenic, Pathogenicrs786204688GRCh38Chr 6, 51748297: 51748297
19PKHD1NM_138694.3(PKHD1): c.1880T> A (p.Met627Lys)SNVPathogenicrs786204696GRCh37Chr 6, 51918920: 51918920
20PKHD1NM_138694.3(PKHD1): c.1830T> A (p.Tyr610Ter)SNVLikely pathogenicrs749293235GRCh38Chr 6, 52055593: 52055593
21PKHD1NM_138694.3(PKHD1): c.2810G> A (p.Trp937Ter)SNVLikely pathogenicrs786204707GRCh37Chr 6, 51908434: 51908434
22PKHD1NM_138694.3(PKHD1): c.7916C> A (p.Ser2639Ter)SNVLikely pathogenicrs181208607GRCh38Chr 6, 51847966: 51847966
23PKHD1NM_138694.3(PKHD1): c.1458C> A (p.Tyr486Ter)SNVLikely pathogenicrs786204749GRCh38Chr 6, 52058377: 52058377
24PKHD1NM_138694.3(PKHD1): c.765C> G (p.Tyr255Ter)SNVPathogenicrs794727037GRCh37Chr 6, 51934268: 51934268
25PKHD1NM_138694.3(PKHD1): c.2854G> A (p.Gly952Arg)SNVPathogenicrs773136605GRCh37Chr 6, 51907900: 51907900
26PKHD1NM_138694.3(PKHD1): c.3528dupC (p.Ser1177Leufs)duplicationPathogenicrs797044713GRCh37Chr 6, 51892986: 51892986
27PKHD1NM_138694.3(PKHD1): c.5060T> C (p.Ile1687Thr)SNVPathogenicrs794727566GRCh37Chr 6, 51889548: 51889548
28PKHD1NM_138694.3(PKHD1): c.5325_5326delAG (p.Val1776Profs)deletionPathogenicrs794727572GRCh37Chr 6, 51887653: 51887654
29PKHD1NM_138694.3(PKHD1): c.5879_5880delCA (p.Thr1960Lysfs)deletionPathogenicrs771180444GRCh37Chr 6, 51824696: 51824697
30PKHD1NM_138694.3(PKHD1): c.7194G> A (p.Trp2398Ter)SNVPathogenicrs794727680GRCh37Chr 6, 51750686: 51750686
31PKHD1NM_138694.3(PKHD1): c.7719dupT (p.Met2574Tyrfs)duplicationPathogenicrs797044745GRCh37Chr 6, 51732675: 51732675
32PKHD1NM_138694.3(PKHD1): c.8411T> A (p.Met2804Lys)SNVLikely pathogenicrs794727759GRCh37Chr 6, 51656063: 51656063
33PKHD1NM_138694.3(PKHD1): c.10219C> T (p.Gln3407Ter)SNVPathogenicrs781368899GRCh37Chr 6, 51524705: 51524705
34PKHD1NM_138694.3(PKHD1): c.10664T> A (p.Ile3555Lys)SNVLikely pathogenicrs794727819GRCh37Chr 6, 51524260: 51524260
35PKHD1NM_138694.3(PKHD1): c.9559delT (p.Ser3187Leufs)deletionPathogenicrs797045101GRCh38Chr 6, 51748057: 51748057
36PKHD1NM_138694.3(PKHD1): c.7560dupT (p.Ala2521Cysfs)duplicationPathogenicrs863224528GRCh38Chr 6, 51868036: 51868036
37PKHD1NM_138694.3(PKHD1): c.8108-?_8173+?deldeletionPathogenicChr na, -1: -1
38PKHD1NM_138694.3(PKHD1): c.1472A> C (p.His491Pro)SNVLikely pathogenicrs886039888GRCh38Chr 6, 52058363: 52058363
39PKHD1NM_138694.3(PKHD1): c.8190delT (p.Glu2731Asnfs)deletionPathogenicrs886042676GRCh37Chr 6, 51695771: 51695771
40PKHD1NM_138694.3(PKHD1): c.5372C> T (p.Pro1791Leu)SNVLikely pathogenicrs886042677GRCh37Chr 6, 51887607: 51887607
41PKHD1NM_138694.3(PKHD1): c.707+1G> ASNVLikely pathogenic, Pathogenicrs748365248GRCh37Chr 6, 51935203: 51935203
42PKHD1NM_138694.3(PKHD1): c.5134G> A (p.Gly1712Arg)SNVLikely pathogenicrs141103838GRCh37Chr 6, 51889474: 51889474
43PKHD1NM_138694.3(PKHD1): c.7967_7968delCA (p.Thr2656Argfs)deletionPathogenicrs886043593GRCh37Chr 6, 51712712: 51712713
44PKHD1NM_138694.3(PKHD1): c.8870T> C (p.Ile2957Thr)SNVPathogenicrs760222236GRCh38Chr 6, 51753281: 51753281
45PKHD1NM_138694.3(PKHD1): c.8068T> C (p.Trp2690Arg)SNVLikely pathogenicrs886061616GRCh38Chr 6, 51847814: 51847814
46PKHD1NM_138694.3(PKHD1): c.8951G> C (p.Gly2984Ala)SNVLikely pathogenicGRCh37Chr 6, 51613463: 51613463
47PKHD1NM_138694.3: c.7084C> TSNVLikely pathogenicChr na, -1: -1
48PKHD1NM_138694.3: c.4593dupTduplicationLikely pathogenicChr na, -1: -1
49PKHD1NM_138694.3: c.603-2A> GSNVLikely pathogenicChr na, -1: -1
50PKHD1NM_138694.3: c.3229-2delAdeletionLikely pathogenicChr na, -1: -1
51PKHD1NM_138694.3: c.5513A> GSNVLikely pathogenicChr na, -1: -1
52PKHD1NM_138694.3: c.10709C> GSNVLikely pathogenicChr na, -1: -1
53PKHD1NM_138694.3: c.11314C> TSNVLikely pathogenicChr na, -1: -1
54PKHD1NM_138694.3: c.4557delTdeletionLikely pathogenicChr na, -1: -1
55PKHD1NM_138694.3: c.5752-2A> GSNVLikely pathogenicChr na, -1: -1
56PKHD1NM_138694.3: c.9470_9473dupCCATduplicationLikely pathogenicChr na, -1: -1
57PKHD1NM_138694.3: c.6910C> TSNVLikely pathogenicChr na, -1: -1
58PKHD1NM_138694.3: c.9683C> ASNVLikely pathogenicChr na, -1: -1
59PKHD1NM_138694.3: c.8050C> TSNVLikely pathogenicChr na, -1: -1
60PKHD1NM_138694.3: c.9901G> TSNVLikely pathogenicChr na, -1: -1
61PKHD1NM_138694.3: c.8764_8765delAGdeletionLikely pathogenicChr na, -1: -1
62PKHD1NM_138694.3: c.2715+2_2715+14del13deletionLikely pathogenicChr na, -1: -1
63PKHD1NM_138694.3: c.9718C> TSNVLikely pathogenicChr na, -1: -1
64PKHD1NM_138694.3: c.7350+1G> TSNVLikely pathogenicChr na, -1: -1
65PKHD1NM_138694.3: c.4121delGdeletionLikely pathogenicChr na, -1: -1
66PKHD1NM_138694.3: c.7270delGdeletionLikely pathogenicChr na, -1: -1
67PKHD1NM_138694.3: c.7893delGdeletionLikely pathogenicChr na, -1: -1
68PKHD1NM_138694.3: c.2192C> ASNVLikely pathogenicChr na, -1: -1
69PKHD1NM_138694.3: c.4822_4823delATdeletionLikely pathogenicChr na, -1: -1
70PKHD1NM_138694.3: c.10826delAdeletionLikely pathogenicChr na, -1: -1
71PKHD1NM_138694.3: c.9743delTdeletionLikely pathogenicChr na, -1: -1
72PKHD1NM_138694.3: c.7866delCdeletionLikely pathogenicChr na, -1: -1
73PKHD1NM_138694.3: c.4574delCdeletionLikely pathogenicChr na, -1: -1
74PKHD1NM_138694.3: c.5452C> TSNVLikely pathogenicChr na, -1: -1
75PKHD1NM_138694.3: c.527+1delGdeletionLikely pathogenicChr na, -1: -1
76PKHD1NM_138694.3: c.6526A> TSNVLikely pathogenicChr na, -1: -1
77PKHD1NM_138694.3: c.2590delAdeletionLikely pathogenicChr na, -1: -1
78PKHD1NM_138694.3: c.7696G> TSNVLikely pathogenicChr na, -1: -1
79PKHD1NM_138694.3: c.3694_3725del32deletionLikely pathogenicChr na, -1: -1
80PKHD1NM_138694.3: c.748C> TSNVLikely pathogenicChr na, -1: -1
81PKHD1NM_138694.3: c.8162delCdeletionLikely pathogenicChr na, -1: -1
82PKHD1NM_138694.3: c.6091delGdeletionLikely pathogenicChr na, -1: -1
83PKHD1NM_138694.3: c.10418delTdeletionLikely pathogenicChr na, -1: -1
84PKHD1NM_138694.3: c.3302delCdeletionLikely pathogenicChr na, -1: -1
85PKHD1NM_138694.3: c.3229-2A> CSNVLikely pathogenicChr na, -1: -1
86PKHD1NM_138694.3: c.4890delGdeletionLikely pathogenicChr na, -1: -1
87PKHD1NM_138694.3: c.3313delTdeletionLikely pathogenicChr na, -1: -1
88PKHD1NM_138694.3: c.5485C> TSNVLikely pathogenicChr na, -1: -1
89PKHD1NM_138694.3: c.1409delGdeletionLikely pathogenicChr na, -1: -1
90PKHD1NM_138694.3: c.3561-2A> GSNVLikely pathogenicChr na, -1: -1
91PKHD1NM_138694.3: c.156dupCduplicationLikely pathogenicChr na, -1: -1
92PKHD1NM_138694.3: c.10972_10973delATdeletionLikely pathogenicChr na, -1: -1
93PKHD1NM_138694.3: c.10109dupTduplicationLikely pathogenicChr na, -1: -1
94PKHD1NM_138694.3: c.7713delTdeletionLikely pathogenicChr na, -1: -1
95PKHD1NM_138694.3: c.10186_10190del5deletionLikely pathogenicChr na, -1: -1
96PKHD1NM_138694.3: c.2264C> TSNVLikely pathogenicChr na, -1: -1
97PKHD1NM_138694.3: c.4882C> GSNVLikely pathogenicChr na, -1: -1
98PKHD1NM_138694.3: c.1205delTdeletionLikely pathogenicChr na, -1: -1
99PKHD1NM_138694.3: c.4141delGdeletionLikely pathogenicChr na, -1: -1
100PKHD1NM_138694.3: c.4_7delACTGdeletionLikely pathogenicChr na, -1: -1
101PKHD1NM_138694.3: c.8832delTdeletionLikely pathogenicChr na, -1: -1
102PKHD1NM_138694.3: c.10199dupTduplicationLikely pathogenicChr na, -1: -1
103PKHD1NM_138694.3: c.448+2T> CSNVLikely pathogenicChr na, -1: -1
104PKHD1NM_138694.3: c.3940delAdeletionLikely pathogenicChr na, -1: -1
105PKHD1NM_138694.3: c.11776delGdeletionLikely pathogenicChr na, -1: -1
106PKHD1NM_138694.3: c.10461dupGduplicationLikely pathogenicChr na, -1: -1
107PKHD1NM_138694.3: c.9856_9859dupAGTTduplicationLikely pathogenicChr na, -1: -1
108PKHD1NM_138694.3: c.6122-3_6122-1delTAGinsAindelLikely pathogenicChr na, -1: -1
109PKHD1NM_138694.3: c.8958delTdeletionLikely pathogenicChr na, -1: -1
110PKHD1NM_138694.3: c.2813delAdeletionLikely pathogenicChr na, -1: -1
111PKHD1NM_138694.3: c.6861delAdeletionLikely pathogenicChr na, -1: -1
112PKHD1NM_138694.3(PKHD1): c.107C> T (p.Thr36Met)SNVPathogenic, protectivers137852944GRCh37Chr 6, 51947999: 51947999
113PKHD1NM_138694.3(PKHD1): c.4991C> T (p.Ser1664Phe)SNVPathogenicrs28937907GRCh37Chr 6, 51889617: 51889617
114PKHD1NM_138694.3(PKHD1): c.9053C> T (p.Ser3018Phe)SNVPathogenicrs137852945GRCh37Chr 6, 51613361: 51613361
115PKHD1NM_138694.3(PKHD1): c.5221G> A (p.Val1741Met)SNVPathogenicrs137852946GRCh37Chr 6, 51889387: 51889387
116PKHD1NM_138694.3(PKHD1): c.8011C> T (p.Arg2671Ter)SNVPathogenicrs137852947GRCh37Chr 6, 51712669: 51712669
117PKHD1NM_138694.3(PKHD1): c.10658T> C (p.Ile3553Thr)SNVPathogenicrs137852948GRCh37Chr 6, 51524266: 51524266
118PKHD1NM_138694.3(PKHD1): c.1486C> T (p.Arg496Ter)SNVPathogenicrs137852949GRCh37Chr 6, 51923147: 51923147
119PKHD1NM_138694.3(PKHD1): c.10412T> G (p.Val3471Gly)SNVPathogenicrs137852950GRCh37Chr 6, 51524512: 51524512
120PKHD1PKHD1, IVS46DS, A-G, +653SNVPathogenicChr na, -1: -1
121PKHD1NM_138694.3(PKHD1): c.10031T> G (p.Leu3344Ter)SNVLikely pathogenic, Pathogenicrs398124475GRCh37Chr 6, 51609308: 51609308
122PKHD1NM_138694.3(PKHD1): c.1602+1G> ASNVPathogenicrs398124476GRCh37Chr 6, 51921687: 51921687
123PKHD1NM_138694.3(PKHD1): c.1694-1G> ASNVPathogenicrs398124477GRCh37Chr 6, 51920528: 51920528
124PKHD1NM_138694.3(PKHD1): c.2341C> T (p.Arg781Ter)SNVPathogenicrs398124478GRCh37Chr 6, 51913356: 51913356
125PKHD1NM_138694.3(PKHD1): c.2407+1G> ASNVPathogenicrs398124479GRCh37Chr 6, 51913289: 51913289
126PKHD1NM_138694.3(PKHD1): c.2452C> T (p.Gln818Ter)SNVPathogenicrs398124480GRCh37Chr 6, 51910942: 51910942
127PKHD1NM_138694.3(PKHD1): c.2827_2828delGA (p.Asp943Hisfs)deletionPathogenicrs398124481GRCh37Chr 6, 51907926: 51907927
128PKHD1NM_138694.3(PKHD1): c.353delG (p.Ser118Ilefs)deletionPathogenicrs398124483GRCh37Chr 6, 51944735: 51944735
129PKHD1NM_138694.3(PKHD1): c.3761_3762delCCinsG (p.Ala1254Glyfs)indelLikely pathogenic, Pathogenicrs398124484GRCh37Chr 6, 51890846: 51890847
130PKHD1NM_138694.3(PKHD1): c.391-1G> CSNVPathogenicrs398124485GRCh37Chr 6, 51941132: 51941132
131PKHD1NM_138694.3(PKHD1): c.4415delGinsTATTCCCC (p.Cys1472Leufs)indelPathogenicrs398124486GRCh37Chr 6, 51890193: 51890193
132PKHD1NM_138694.3(PKHD1): c.5236+1G> ASNVPathogenicrs398124487GRCh37Chr 6, 51889371: 51889371
133PKHD1NM_138694.3(PKHD1): c.682A> G (p.Ser228Gly)SNVLikely pathogenicrs398124491GRCh37Chr 6, 51935229: 51935229
134PKHD1NM_138694.3(PKHD1): c.8407T> C (p.Cys2803Arg)SNVLikely pathogenicrs398124495GRCh37Chr 6, 51656067: 51656067
135PKHD1NM_138694.3(PKHD1): c.8408G> A (p.Cys2803Tyr)SNVLikely pathogenicrs398124496GRCh37Chr 6, 51656066: 51656066
136PKHD1NM_138694.3(PKHD1): c.85G> T (p.Glu29Ter)SNVPathogenicrs398124498GRCh37Chr 6, 51948021: 51948021
137PKHD1NM_138694.3(PKHD1): c.8824C> T (p.Arg2942Ter)SNVLikely pathogenic, Pathogenicrs398124500GRCh37Chr 6, 51618125: 51618125
138PKHD1NM_138694.3(PKHD1): c.930delC (p.Thr311Leufs)deletionPathogenicrs398124501GRCh37Chr 6, 51929799: 51929799
139PKHD1NM_138694.3(PKHD1): c.9689delA (p.Asp3230Valfs)deletionPathogenicrs398124502GRCh37Chr 6, 51612725: 51612725
140PKHD1NM_138694.3(PKHD1): c.982C> T (p.Arg328Ter)SNVLikely pathogenic, Pathogenicrs398124503GRCh37Chr 6, 51927453: 51927453

Expression for genes affiliated with Polycystic Kidney and Hepatic Disease

About this section
Search GEO for disease gene expression data for Polycystic Kidney and Hepatic Disease.

Pathways for genes affiliated with Polycystic Kidney and Hepatic Disease

About this section

GO Terms for genes affiliated with Polycystic Kidney and Hepatic Disease

About this section

Cellular components related to Polycystic Kidney and Hepatic Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1polycystin complexGO:000213310.7PKD1, PKD2
2TSC1-TSC2 complexGO:003359610.4TSC1, TSC2
3ciliary basal bodyGO:003606410.2IFT88, PKD2, PKHD1
4ciliary membraneGO:00601709.5PKD1, PKD2, PKD2L1
5ciliumGO:00059298.9IFT88, INVS, NPHP3, PKD1, PKD2, PKHD1L1

Biological processes related to Polycystic Kidney and Hepatic Disease according to GeneCards Suite gene sharing:

(show all 23)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycleGO:003165910.7PKD1, PKD2
2cytoplasmic sequestering of transcription factorGO:004299410.7PKD1, PKD2
3metanephric ascending thin limb developmentGO:007221810.7PKD1, PKD2
4placenta blood vessel developmentGO:006067410.7PKD1, PKD2
5nitrogen compound metabolic processGO:000680710.6PKD1, PRKCSH
6kidney morphogenesisGO:006099310.5HNF1B, NPHP3
7mesonephric duct developmentGO:007217710.4HNF1B, PKD1, PKD2
8mesonephric tubule developmentGO:007216410.4HNF1B, PKD1, PKD2
9regulation of calcium ion importGO:009027910.4EGF, PKD2
10branching morphogenesis of an epithelial tubeGO:004875410.3EGF, HNF1B, PKD1
11renal system developmentGO:007200110.3PKD1, PKD2, PRKCSH
12determination of liver left/right asymmetryGO:007191010.2NPHP3, PKD2
13negative regulation of macroautophagyGO:001624210.1MTOR, TSC1
14negative regulation of cell sizeGO:004579210.0MTOR, TSC1
15liver developmentGO:000188910.0HNF1B, PKD1, PKD2, PRKCSH
16regulation of cAMP metabolic processGO:00308149.9NPHP3, PKD2
17detection of mechanical stimulusGO:00509829.8PKD1, PKD2, PKD2L1
18spinal cord developmentGO:00215109.8MTOR, PKD1, PKD2
19positive regulation of gene expressionGO:00106289.4AVPR2, HNF1B, MTOR, PKD2
20peptidyl-serine phosphorylationGO:00181059.3EPO, MTOR, PKD1, PRKD1
21cell cycle arrestGO:00070509.3MTOR, PKD1, PKD2, TSC1, TSC2
22kidney developmentGO:00018229.3HNF1B, NPHP3, PKD1, PKD2, PKHD1, TSC1
23positive regulation of neuron projection developmentGO:00109769.2EPO, MTOR, PRKD1

Molecular functions related to Polycystic Kidney and Hepatic Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1muscle alpha-actinin bindingGO:005137110.4PKD2, PKD2L1
2ion channel bindingGO:004432510.4PKD1, PKD2, PRKCSH
3alpha-actinin bindingGO:005139310.3PKD2, PKD2L1
4calcium channel activityGO:000526210.0PKD1, PKD2, PKD2L1
5phosphoprotein bindingGO:005121910.0MTOR, PKD2, PRKCSH
6protein bindingGO:00055153.5AVPR2, CFTR, EGF, EPO, HNF1B, IFT88

Sources for Polycystic Kidney and Hepatic Disease

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet